Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Verve Therapeutics, a clinical-stage biotechnology company focused on genetic medicines for cardiovascular disease, has granted 5,330 restricted stock units (RSUs) to a new employee under its 2024 Inducement Stock Incentive Plan. The grant, made on November 29, 2024, complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in equal annual installments over four years starting January 1, 2025, contingent on continued employment.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VERV gained 27.63%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29, 2024, the company granted equity awards to one new employee, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such employee’s continued service with the company on each such vesting date.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
How many RSUs did Verve Therapeutics (VERV) grant to new employees on November 29, 2024?
What is the vesting schedule for Verve Therapeutics (VERV) RSUs granted in November 2024?
Under which plan did Verve Therapeutics (VERV) issue its November 2024 inducement grants?
